{
    "organizations": [],
    "uuid": "b0ffa643a1582f221ef0ef3ee49eb16aa7881edd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aradigm-fda-advisory-committee-did/brief-aradigm-fda-advisory-committee-did-not-recommend-approval-for-linhaliq-idUSFWN1P60WO",
    "ord_in_thread": 0,
    "title": "BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 11 (Reuters) - Aradigm Corp:\n* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​\n* ARADIGM CORP - ‍FDA HAS SET A PDUFA ACTION DATE OF JANUARY 26, 2018 FOR COMPLETION OF ITS REVIEW OF LINHALIQ​\n* ARADIGM CORP - ‍FDA ADAC DID NOT RECOMMEND APPROVAL FOR LINHALIQ AS A TREATMENT FOR NCFBE PATIENTS WITH CHRONIC LUNG PSEUDOMONAS AERUGINOSA INFECTIONS​\n* ARADIGM - ADAC VOTED 12 “NO” TO 3 “YES”, 1 ABSTENTION, ON QUESTION OF CO‘S PROVISION OF EVIDENCE OF SAFETY & EFFICACY OF CIPROFLOXACIN DISPERSION Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-12T06:06:00.000+02:00",
    "crawled": "2018-01-12T18:33:33.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "aradigm",
        "corp",
        "aradigm",
        "report",
        "result",
        "fda",
        "advisory",
        "committee",
        "meeting",
        "aradigm",
        "corp",
        "set",
        "pdufa",
        "action",
        "date",
        "january",
        "completion",
        "review",
        "aradigm",
        "corp",
        "adac",
        "recommend",
        "approval",
        "linhaliq",
        "treatment",
        "ncfbe",
        "patient",
        "chronic",
        "lung",
        "pseudomonas",
        "aeruginosa",
        "aradigm",
        "adac",
        "voted",
        "yes",
        "abstention",
        "question",
        "co",
        "provision",
        "evidence",
        "safety",
        "efficacy",
        "ciprofloxacin",
        "dispersion",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}